References
1. Semsarian Ch., Ingles J., Maron M.S., et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. JACC. 2015; 65 (12): 1249-54.
2. Spirito P., Autore C., Formisano F., et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014; 113: 1550-55.
3. Writing Committee Members; Ommen S.R., Mital S., Burke M.A., Day S.M., Deswal A., Elliott P., et al.
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2021; 162 (1): e23-106. DOI: https://doi.org/10.1016/j.jtcvs.2021.04.001 Epub 2021 Apr 27. PMID: 33926766.
4. Authors/Task Force members; Elliott P.M., Anasta-sakis A., Borger M.A., Borggrefe M., Cecchi F., Charron P., et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35 (39): 2733-79. DOI: https://doi.org/10.1093/eurheartj/ehu284 Epub 2014 Aug 29. PMID: 25173338.
5. Richards S., Aziz N., Bale S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17: 405-24.
6. Dzemeshkevich S.L., Motreva A.P., Kalmykova O.V., Martyanova Yu.B., Sinitsyn V.E., Mershina E.A., et al. Hypertrophic cardiomyopathy in youth: phenotype, genotype, and treatment approaches. Clinical and Experimental Surgery. Petrovsky Journal. 2019; 7 (3): 54-62. DOI: https://doi.org/10.24411/2308-1198-2019-13006 (in Russian)
7. Dzemeshkevich S.L., Stevenson L. Mitral valve disease. Function, diagnosis, treatment Moscow: GEOTAR-Media, 2015 (in Russian)
8. Kirklin J.W., Barrat-Boyes B.G. Cardiac surgery. New York: Churchill Livingstone, 1986.
9. Pare J.A.P., Fraser R.O., Pirozinski W.J., et al. Hereditary cardiovascular dysplasia. A form of familial cardiomyopathy. Am J Med. 1961; 31: 37-62.
10. Gesterfer-Lowrance A., Kass S., Tanigawa G., et al. A molecular basis for familial hypertrophic cardiomyopathy: a p-cardiac myosin heavy chain gene missense mutation. Cell. 1990; 62 (5): 999-1006.
11. McKenna W., Deanfield J., Faruqui A., et al. Prognosis in hypertrophic cardiomyopathy: role of age and hemodynamic features. Am J Cardiol. 1981; 47: 532-8.
12. Maron B.J., Braunwald E. Evolution of hypertrophic cardiomyopathy to a contemporary treatable disease. Circulation. 2012; 126: 1640-4.
13. O’Gara P.T., Bonow R.O., Maron B.J., et al. Myocardial perfusion abnormalities in patient with HCM assessment with thallium-201 emission computed tomography. Circulation. 1987; 76: 1214-23.
14. Nishimura R.A., Shaff H.V. Septal myectomy for patients with hypertrophic cardiomyopathy: a new paradigm. J Thorac Cardiovasc Surg. 2016; 151: 303-4.
15. Goodwin J.F., Oakley C.M. The cardiomyopathies (editorial). Br Heart J. 1972; 34: 545-52.
16. Dzemeshkevich S.L., Frolova Yu.V., Kim S.Yu., Fedorov D.N., Zaklyaz’minskaya E.V., Fedulova S.V., et al. Anatomic and morphological signs of a diffuse-generalized hypertrophic cardiomyopathy. Rossiyskiy kardio-logicheskiy zhurnal [Russian Journal of Cardiology]. 2015; 5 (121): 58-63. DOI: https://doi.org/10.15829/1560-4071-2015-05-58-63 (in Russian)
17. Dzemeshkevich S.L., Frolova Yu., Sinitsin V., et al. Reconstructive surgery for the diffuse generalized form of hypertrophic cardiomyopathy. WSCTS J. 2017; 2: 31-5.